The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis
https://doi.org/10.14412/1996-7012-2013-278
Abstract
The meeting of the Russian Council of Experts for the use of the novel anabolic agent Forsteo®(teriparatide) to treat osteoporosis (OP) was held in Moscow on June 29, 2013. The meeting was attended by leading Russian OP specialists, including the members of the Russian Osteoporosis Association and its Presidium. The participants of the Council of Experts noted the great social importance of severe OP, which was associated primarily with its consequences, such as fractures causing an increase in disability and mortality rates in elderly people, and discussed the possibilities and benefits of the new approach to treating OP with teriparatide, the first drug permitting the formation of new bone tissue. The experts have recommended teriparatide for use within the registered indications in the following groups of patients: those who have severe OP (≥1 vertebral fractures, hip fracture of vertebral bodies or a fracture of the proximal femur, multiple recurrent fractures of skeletal bones) as first-line therapy; those who had ineffective previous antiosteoporotic therapy (new fractures occurring during the treatment and/or a continuing decline in bone mineral density), those who are intolerant to other medications for OP, or who have contraindications to their use.
About the Author
Olga Mikhailovna Lesnyak
Ural State Medical Academy, Ministry of Health of Russia, Yekaterinburg
Russian Federation
Russian Federation
References
1. <div><p>McClung MR, Martin JS, Miller PD et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165(15):1762–8. DOI: 10.1001%2Farchinte.165.15.1762.</p><p>Paschalis EP, Glass EV, Donley DW, Eriksen EF. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab. 2005;90(8):4644–9. DOI: 10.1210%2Fjc.2004-2489. Epub 2005 May 24.</p><p>Prevrhal S, Krege JH, Chen P et al. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin. 2009;25(4):921–8. DOI: 10.1185/03007990902790993.</p><p>Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41. DOI: 10.1056%2FNEJM200105103441904.</p><p>Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(1):18–23. DOI:10.1359%2Fjbmr.2003.18.1.18.</p><p>Obermayer-Pietsch BM, Marin F, McCloskey EV et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorbtive treatment. J Bone Miner Res. 2008;23(10):1591–600. DOI: 10.1359/jbmr.080506.</p><p>Prince R, Sipos A, Hossain A et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005;20(9):1507–413. DOI: 10.1359%2FJBMR.050501. Epub 2005 May 2.</p><p>Kanis JA, McCloskey EV, Johansson H et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57. DOI: 10.1007/s00198-012-2074-y. Epub 2012 Oct 19.</p><p>Nelson BW, Bilezikian JP, Camacho PM et al. American association of clinical endocrinologists medical duidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endoc Pract. 2010;16(Suppl 3):1–37.</p><p>Genant HK, Halse J, Briney WG et al. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin. 2005;21(7):1027–34. DOI: 10.1185%2F030079905X49671.</p></div><br />
Review
For citations:
Lesnyak OM. The Russian Council of Experts for Use of the Innovative Anabolic Agent Forsteo®(Teriparatide) in the Treatment of Severe Osteoporosis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2013;7(3):76-78. (In Russ.) https://doi.org/10.14412/1996-7012-2013-278
Views:
2080
Email this article 